Matinas BioPharma Investor Presentation Deck

27 Expanding LNC Intellectual Property Portfolio Continuingly increasing our patent suite to increase protection and exclusivity 0 + MAT2203 potentially entitled to 12+ years of exclusivity (QIDP & Orphan status) Global Platform IP base protection out to 2037 with 20 patents issued in last 5 years Strong IP & Regulatory Designations COPYRIGHT MATINAS BIOPHARMA 2024 Im Recent patent applications based on formulation work with small oligonucleotides MATINAS BIOPHARMA

View entire presentation